Great news indeed on open label extension for trial sites.

New Post Public Reply Private Reply Replies (2) Message Board
HCIT smurph #69670
1,034
Great news indeed on open label extension for trial sites. I found this link on exactly what label extension means. Very interesting and IMO, it's just the beginning of Vyrologix's uses and I could be wrong but it could pave the way for other indications down the road, I hope but I am not definite on it but very happy it was granted for CV-19

Open-label extension studies: do they provide meaningful information on the safety of new drugs?


Abstract

The number of open-label extension studies being performed has increased enormously in recent years. Often it is difficult to differentiate between these extension studies and the double-blind, controlled studies that preceded them. If undertaken primarily to gather more patient-years of exposure to the new drug in order to understand and gain confidence in its safety profile, open-label extension studies can play a useful and legitimate role in drug development and therapeutics. However, this can only occur if the open-label extension study is designed, executed, analysed and reported competently. Most of the value accrued in open-label extension studies is gained from a refinement in the perception of the expected incidence of adverse effects that have most likely already been identified as part of the preclinical and clinical trial programme. We still have to rely heavily on post-marketing safety surveillance systems to alert us to type B (unpredictable) adverse reactions because open-label extension studies are unlikely to provide useful information about these types of often serious and relatively rare adverse reactions. Random allocation into test and control groups is needed to produce precise incidence data on pharmacologically expected, or type A, adverse effects. Some increased confidence about incidence rates might result from the open-label extension study; however, as these studies are essentially uncontrolled and biased, the data are not of great value. Other benefits have been proposed to be gained from open-label extension studies. These include ongoing access to an effective but otherwise unobtainable medicine by the volunteers who participated in the phase III pivotal trials. However, there are unappreciated ethical issues about the appropriateness of enrolling patients whose response to previous treatment is uncertain, largely because treatment allocation in the preceding randomised, double-blind, controlled trial has not been revealed at the time of entry into the open-label extension study. Negative aspects of open-label extension studies revolve around their use as a marketing tool, as they build a market for the drug and generate pressure for subsidised access to the drug from consumers and their physicians. Consumers, institutions where these studies are conducted and research ethics committees need to be convinced of the motives, as well as the quality, of the open-label extension study and its execution before supporting such studies. Open-label extension studies do have a legitimate but limited place in the clinical development of new medicines. The negative perceptions about these studies have arisen because of perversion of acceptable rationales for this type of study and a failure to recognise (or disclose) the limitations resulting from the inherent weaknesses in their design. Increased human exposure to a new medicine under reasonably controlled circumstances to increase confidence in the safety of the medicine is an acceptable rationale for an open-label extension study, and a useful activity to increase the knowledge of the safety profile of a new medicine. However, this goal is increasingly being achieved by means other than open-label extension studies.

Here is the entire link to the abstract. I hope I'm doing some justice on this definition

https://pubmed.ncbi.nlm.nih.gov/17253876/

GLTA and this is a definite Christmas present for those in severe or critical condition in our 15 or so trial sites that need Leronlimab/Vyrologix

HCIT

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
https://media.gettyimages.com/photos/the-grea...wdoE_swYM=
Scroll down for more posts ▼

Top 10 Most Recent News Articles

UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 362

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 39

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 481

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 298

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 527

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 419

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 583

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 90

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 407

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading

Top 5 Most Recently Viewed Articles

Sentry Insurance Company Announces Strategic Acquisition Plans

Updated Category News Views 205

Insights into Sentry Insurance Company's Acquisition Strategy OLDWICK, N.J.--AM Best has announced that the Credit Ratings of Sentry Insurance Company, along with its subsidiaries—collectively known as Sentry—will stay stable after the recent news of their acquisition of The General from American Family Insurance Group. This deal includes Permanent General Assurance...

Continue Reading
Growth Outlook for the Automotive Horn System Market

Updated Category News Views 165

Overview of the Automotive Horn System Market Wilmington, Delaware - A recent market analysis reveals a significant shift in the automotive horn system industry. The report estimates that the market, currently valued at $0.7 billion, is projected to grow to $1.8 billion by the end of the forecast period in 2033, achieving an impressive compound annual growth rate (CAGR)...

Continue Reading
Payoneer Completes Warrant Purchase Offer and Amendments

Updated Category News Views 105

Payoneer Completes Warrant Purchase Offer and Consent Solicitation Payoneer Global Inc. (NASDAQ: PAYO), a financial technology company serving businesses worldwide, has completed its cash offer to buy outstanding Warrants at $0.78 each. The move is designed to simplify Payoneer’s capital structure and give warrant holders a clear cash alternative, while keeping the...

Continue Reading
The Aesthetic Medicine Market's Future: Key Trends to Watch

Updated Category News Views 251

Sales Expectations for the Aesthetic Medicine Market The global aesthetic medicine market was estimated at US$ 83.12 billion recently, with projections indicating a remarkable potential to rise to US$ 233.67 billion by the year 2033. This growth is anticipated at a compound annual growth rate (CAGR) of 12.17% from 2025 through to 2033. Impact of Technological Innovations...

Continue Reading
Bauducco's Florida Expansion Boosts U.S. Manufacturing

Updated Category News Views 74

New Facility Marks a Strategic Shift for Bauducco Imagine three generations crafting baked goods, and then picture this: Bauducco, the Brazilian icon for snacks like wafer cookies and Panettone, boldly stepping onto the U.S. manufacturing stage. They have just swung wide the doors of their largest stateside factory, right in Zephyrhills, Florida. They're not here to...

Continue Reading